Gilead Sciences Inc. unveiled topline data on 1 June from a Phase III study of its antiviral remdesivir in moderately ill COVID-19 patients that increase the evidence suggesting the drug can offer a treatment benefit, but at the same time raise as many questions as they answer.
The data from the 584-patient SIMPLE study add to findings from a placebo-controlled study run by the US National Institute...






